TOT BIOPHARM International Company Limited (1875.HK)
- Previous Close
1.580 - Open
1.580 - Bid 1.550 x --
- Ask 1.680 x --
- Day's Range
1.530 - 1.680 - 52 Week Range
0.800 - 3.400 - Volume
20,800 - Avg. Volume
38,446 - Market Cap (intraday)
1.298B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.050 - Earnings Date Mar 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.89
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops TAB008 for the treatment of non-squamous non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, fallopian tube cancer, or primary peritoneal cancer, and hepatocellular carcinoma. It also offers TOZ309 for the treatment of glioblastoma multiforme or anaplastic astrocytoma. In addition, the company develops TAA013 for HER2+ breast cancer; TAE020 which is under preclinical trial for acute myeloid leukemia; and TAB014 for wet age-related macular degeneration. Further it develops TAC020 for the treatment various solid tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China.
www.totbiopharm.comRelated News
Performance Overview: 1875.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1875.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1875.HK
Valuation Measures
Market Cap
1.30B
Enterprise Value
1.29B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.44
Price/Book (mrq)
1.75
Enterprise Value/Revenue
1.65
Enterprise Value/EBITDA
-39.65
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.84%
Return on Assets (ttm)
-1.54%
Return on Equity (ttm)
-5.39%
Revenue (ttm)
780.63M
Net Income Avi to Common (ttm)
-37.76M
Diluted EPS (ttm)
-0.050
Balance Sheet and Cash Flow
Total Cash (mrq)
351.6M
Total Debt/Equity (mrq)
50.34%
Levered Free Cash Flow (ttm)
--
Research Analysis: 1875.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 1875.HK
1875.HK does not have Company Insights